RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
The new patent expands the robust patent portfolio covering RHB-104 and RHB-204 RedHill plans to initiate a pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections in the second half of 2019 …